Merck Starts Phase 2b/3 Trial of Neovascular Age-Related Macular Degeneration Treatment

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201), a novel investigational bispecific antibody that directly activates Tie2 signaling and inhibits vascular endothelial growth factor (VEGF), for the treatment of neovascular (wet) age-related macular degeneration (NVAMD).

https://www.stocktitan.net/news/MRK/merck-announces-initiation-of-pivotal-phase-2b-3-trial-evaluating-mk-1amzwxl3khph.html